Jove
Visualize
Contact Us

Related Experiment Videos

What should the optimal target hemoglobin be?

Juan M López Gómez1, Fernando Carrera

  • 1Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Kidney International. Supplement
|May 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sleep and cardiometabolic risk. Narrative revision.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2023
Same author

Better Anti-Spike IgG Antibody Response to SARS-CoV-2 Vaccine in Patients on Haemodiafiltration than on Haemodialysis.

Blood purification·2023
Same author

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
.

Clinical nephrology·2017
Same author

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2017
Same author

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

BMC nephrology·2017
Same author

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.

PloS one·2016
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Correcting anemia in chronic kidney disease (CKD) patients offers benefits. Individualized hemoglobin targets are recommended, balancing advantages against potential risks in certain patient groups.

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Background:

  • Partial anemia correction in chronic kidney disease (CKD) alleviates symptoms.
  • Debate exists on whether full anemia correction offers superior benefits compared to partial correction.

Purpose of the Study:

  • To evaluate the benefits and risks of normalizing hemoglobin (Hb) levels in CKD patients.
  • To determine optimal hemoglobin targets for CKD patients.

Main Methods:

  • Review of existing studies on anemia correction in CKD.
  • Analysis of the relationship between hematocrit (Hct) levels, mortality, and morbidity in dialysis patients.
  • Examination of outcomes in CKD patients with normalized Hb, particularly those with cardiac conditions.

Related Experiment Videos

Main Results:

  • Normalization of Hb may improve cardiac function and cognitive abilities in CKD patients.
  • Higher Hct levels correlate with reduced mortality and morbidity in dialysis patients.
  • Increased mortality is observed in specific patient groups (cardiac disease, heart failure) when Hb is normalized.

Conclusions:

  • While normalizing Hb benefits many CKD patients, risks exist for certain individuals.
  • Individualized Hb targets are crucial, considering patient-specific factors like age, comorbidities, and cardiac status.